




RealRate

PHARMACEUTICAL 2017

Zosano Pharma Corp Rank 243 of 292





RealRate

PHARMACEUTICAL 2017

Zosano Pharma Corp
Rank 243 of 292



The relative strengths and weaknesses of Zosano Pharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zosano Pharma Corp compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Zosano Pharma Corp is the variable Net Income, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is -119%, being 121% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	15,276
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,819
Liabilities, Non-Current	0
Other Assets	175
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	6,602
Other Net Income	-1,199
Other Revenues	0
Property and Equipment	5,455
Research and Development	20,457
Selling, General and Administrative Expense	8,176

Output Variable	Value in 1000 USD
Assets	20,906
Liabilities	16,421
Expenses	28,633
Revenues	0
Stockholders Equity	4,485
Net Income	-29,832
Comprehensive Net Income	-29,832
Economic Capital Ratio	-119%